Chr. Hansen acquires Jennewein Biotechnologie to strengthen lead in HMO market
Jennewein’s products will have functional synergies with Chr. Hansen’s probiotic bacteria, such as LGG and BB-12, and combining the companies will create competitive advantage.
Chr. Hansen has entered into an agreement to acquire Jennewein Biotechnologie, a German biotechnology company. The acquisition complements with Chr. Hansen’s 2025 Strategy of pursuing bolt-on acquisitions that extend and strengthen its microbial and fermentation technology platforms.
Dr Stefan Jennewein, founder and CEO of Jennewein, commented: “Today, HMOs [human milk oligosaccharides] have become a must-have for all premium infant formula. Whereas initially we were very much intrigued by the anti-infective effects of HMOs, in particular against human pathogenic viruses, today it is clear that even more beneficial effects can be expected from the combination of HMOs with probiotics. Thus, Chr. Hansen is the perfect match for Jennewein to bring the HMO story to the next level.”
HMOs are essential groups of milk sugars found only in human breast milk, and are essential to developing a healthy digestive system in infants. HMOs are synergistic with probiotics, and help to and strengthen a well-balanced microbiota, support the development of a strong immune function, and protect infants from infections.
Mauricio Graber, CEO of Chr. Hansen, said: “The fast-growing market is a new space that we have been following with strong interest for some years. In truth, we are making a long-term investment and commitment to HMOs, which I am convinced will bring long-term value creation to our shareholders. HMO also fit with our purpose to, ‘Grow a better world. Naturally’, as these are some of nature’s most intricate nutritional components for the most precious and vulnerable – newborn infants and young children.
“Jennewein’s products will have strong functional synergies with our probiotic bacteria, such as LGG and BB-12, and combining the companies will create an even strong competitive advantage.”